VAKCINA

U POGONU "Hemofarma", dok se čeka početak proizvodnje "sinofarm" vakcine u našoj zemlji, napunjeno je 480.000 doza ovog cepiva, koje su trenutno u postupku kontrole kvaliteta. Očekuje se da će ta procedura biti završena sledeće nedelje, a vakcine na tržištu - u februaru. Mesec, najviše dva, kasnije, trebalo bi i zvanično da počne proizvodnja vakcina ovog kineskog proizvođača u novoj fabrici u Srbiji, i to po tri miliona doza mesečno.

Direktorka RFZO Sanja Radojević Škodrić kaže da je plan da se prozvodnja odvija u dve faze:

- Prva faza, koja obuhvata punjenje i pakovanje uvezene supstance, počeće već u martu i aprilu. Druga faza, odnosno celokupan proces i proizvodnja aktivne supstance, radiće se u novoj fabrici krajem sledeće godine. Ne čekamo izgradnju fabrike, već smo krenuli sa punjenjem u "Hemofarmu", gde će se puniti do otvaranja nove fabrike - kaže Radojević Škodrić.

"Sinofarmova" vakcina prvo će se proizvoditi za Srbiju, a zatim i za izvoz u region i ostale zemlje.

"I think it is clear that omicron has higher transmission rate. That part, we are pretty sure of," Randall N. Hyer, senior vice president of Moderna, said in a recent interview with Yonhap News Agency in Seoul. "In terms of effectiveness against (COVID-19) vaccines, we don't know yet." (...)
"We have three lines of defense (against the omicron variant) in parallel," Hyer said. "Yet, we don't know which one will be the most successful."
Under the first strategy, Moderna has completed a safety and immunogenicity study of administering a high dose of its existing mRNA vaccine as a booster.
"We already have clinical data on boosters ... we want to know how it works on omicron," the senior executive said, adding the results of initial data are expected in the next two to three weeks.
The senior vice president said the second stage is studying two multivalent booster candidates in the clinic, which are designed to anticipate mutations that have emerged in the omicron variant.
The third strategy, currently pursued by Moderna and its rivals, is to develop omicron-tailored vaccines that can be administered as a booster shot following full vaccination.
The vaccine expert also said such booster vaccines can be administered with COVID-19 vaccines from other manufacturers, noting such a mix-and-match regimen is both effective and safe.
As to a question of the earliest timing on the results, Hyer said Moderna is moving as fast as it can with all three strategies equally in mind.

Talason wrote:

kondo wrote:vezano za omikron, podsetio bih da je velika vecina nas sustinski vakcinisana samo sa jednom dozom vakcine, da dve prve kineske mozemo da okacimo macku o rep. dok ne primimo drugi mRNA buster, krckamo se na tihoj vatri pa ko se opece, opece.

Možda je baš suprotno.

#SIMPOSIOCORONAVAC - Presidente do Butantan, Dimas Covas, abre simpósio e CEO da Sinovac, Weidong Yin, afirma que a farmacêutica já está desenvolvendo novo imunizante com base na cepa Ômicron. Veja mais em https://t.co/gfycQxlB1y

— Instituto Butantan (@butantanoficial) December 7, 2021

President of Butantan, Dimas Covas, opens a symposium and CEO of Sinovac, Weidong Yin, says that the pharmaceutical company is already developing a new immunizing agent based on the Omicron strain. See more at https://butantan.gov.br/noticias/simposio-internacional-comeca-com-declaracoes-do-butantan-e-sinovac-e-expectativa-de-atualizacao-da-coronavac-contra-variantes

China has approved trials for the use of a domestically developed mRNA Covid-19 vaccine as a booster shot — a development that could widen the options for China’s vaccination campaign.
The Ministry of Science and Technology said it had approved clinical trials on the efficacy and safety of using the vaccine, which uses advanced genetic techniques to trigger an immune response, on adults who have already been given vaccines made using inactivated material from the coronavirus.
The vaccine, ARCoVax, was jointly developed by the Academy of Military Medical Sciences, Suzhou Abogen Biosciences and Walvax Biotechnology. It is being tested in global multi-site final stage human trials, which hope to recruit about 30,000 participants. Trial participants in Mexico were inoculated in September and in Malaysia last month.

Slovakia’s Parliament has approved a plan to give people 60 and older up to 300 euros ($339) if they are vaccinated against COVID-19. https://t.co/mISnIqH5wK

— ABC News Politics (@ABCPolitics) December 9, 2021

Freja Kirsebom, 5h, 11 tweets, 2 min read


Our first initial estimates of vaccine effectiveness (VE) against symptomatic disease with the Omicron variant are now out. In short, VE remains high following a Pfizer booster after AZ or Pfizer, but is reduced after two doses.

More below

We used a test negative case control design to estimate VE against symptomatic COVID-19 with the Omicron variant compared to Delta. The odds of vaccination in PCR positive cases was compared to the odds of vaccination in those who test negative.

Pillar 2 tests were classified as either Delta or Omicron from the period 27/11 – 6/12 based on sequencing and SGFT where sequencing wasn’t available. From 27/11, at least 80% of PCR tests which included the S-gene as a target and which had SGTF were the Omicron variant.

581 symptomatic Omicron cases were identified during the study period which could be linked to the vaccine record. Over the same period there were 56,439 eligible Delta cases and 130,867 test negative controls.

Among those who received AZ as the primary course, from two weeks after a Pfizer booster, VE increased to 71.4% (95%CI: 41.8 to 86.0%). Among those who had received Pfizer as the primary course, VE increased to 75.5% (95%CI: 56.1 to 86.3%) after the booster.



Our findings show that VE against symptomatic disease with the Omicron variant is lower than with the Delta variant, although moderate to high VE of 70-75% is seen in the early period after a booster.

Due to the small numbers of Omicron cases detected and the time-lag between infection and severe disease, we have not yet been able to determine how protective the vaccines are against severe outcomes.

However - previous experience with the Delta variant suggests that protection against hospitalisation after two doses is well maintained. We will be looking at this as soon as there is enough data!

These findings are based on small numbers of cases with the Omicron variant and our estimates are subject to significant uncertainty with wide confidence intervals. This will improve as more data become available.

Our findings support maximising coverage with booster doses in highly vaccinated populations. Further follow-up will be needed to assess VE against more severe outcomes (such as hospitalisation) as well as the duration of protection of the booster vaccine.

Full pre-print here: khub.net/documents/1359…

Booster vaccines queues have formed across the country for the second day running

Read more: https://t.co/H8QDZPBDLr pic.twitter.com/3vUsPD9KN7

— The Telegraph (@Telegraph) December 14, 2021

Nigeria and Senegal will destroy about 1.4 million COVID-19 vaccines which are set to expire - REU

— BNO Newsroom (@BNODesk) December 14, 2021

European Union governments have agreed to buy more than 180 million doses of the Pfizer-BioNTech's COVID-19 vaccine that has been adapted for the Omicron variant of the coronavirus https://t.co/DQ5zMnv1IN pic.twitter.com/XA2CevwYdw

— Reuters (@Reuters) December 17, 2021

Cousin Billy wrote:u svetlu novih podataka o Sinofarmu, mislim da će biti znatne revizije statusa našeg zelenog sertifikata u Evropi. a šta ovo znači za stariju populaciju, ne smem ni da nagađam. za 65+ ne postoji nikakav blagi kovid.

COVID-19 vaccines will not be enough to withstand the Omicron variant, warned the CEO of BioNTech, the German company behind the mRNA vaccine produced with Pfizer.

"We must be aware that even triple-vaccinated are likely to transmit the disease…It is obvious we are far from 95 per cent effectiveness that we obtained against the initial virus," Ugur Sahin told the French daily Le Monde in an interview published on Monday.

The latest research from South Africa, where Omicron was first reported, suggested that two doses of the Pfizer/BioNTech vaccine offered 70 per cent effectiveness in reducing the risk of hospitalisation.

“There will be a loss of effectiveness against Omicron over time, it's very likely, but it's still to be measured how quickly. I will not base predictions on preliminary laboratory data but on real-life data, which is much more appropriate,” the German immunologist said.

Sahin said testing for COVID-19 is important, especially for the elderly and during winter, as are other protective measures such as mask-wearing, adding, “otherwise we will not be able to control the rapid expansion of this new variant.”

“We remain on track with our 100-day target, which means we should be able to deliver our first suitable vaccines to Omicron in March, subject to regulatory approval,” he said.

CEO of BioNTech Ugur Sahin wrote:“We remain on track with our 100-day target, which means we should be able to deliver our first suitable vaccines to Omicron in March, subject to regulatory approval,” he said.